<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:07:40 -0700</creation_date>
  <update_date>2013-01-15 20:07:40 -0700</update_date>
  <accession>HMDBP08204</accession>
  <secondary_accessions>
    <accession>13915</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>GABA(A) receptor subunit beta-1</synonym>
  </synonyms>
  <gene_name>GABRB1</gene_name>
  <general_function>Involved in ion transport</general_function>
  <specific_function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00492</accession>
      <name>Chlorine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00112</accession>
      <name>Gamma-Aminobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14332</accession>
      <name>Lorazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14335</accession>
      <name>Ethchlorvynol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14376</accession>
      <name>Temazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14493</accession>
      <name>Clobazam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13943</accession>
      <name>Alpha-hydroxyalprazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14575</accession>
      <name>Lindane</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14618</accession>
      <name>Chlordiazepoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14686</accession>
      <name>Adinazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14766</accession>
      <name>Clorazepate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14821</accession>
      <name>Midazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14828</accession>
      <name>Flurazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14939</accession>
      <name>Halazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14980</accession>
      <name>Oxazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15034</accession>
      <name>Triazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15201</accession>
      <name>Clonazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15346</accession>
      <name>Estazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15507</accession>
      <name>Gamma Hydroxybutyric Acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15511</accession>
      <name>Bromazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15512</accession>
      <name>Clotiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15513</accession>
      <name>Fludiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15526</accession>
      <name>Ketazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15527</accession>
      <name>Prazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15528</accession>
      <name>Quazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15533</accession>
      <name>Cinolazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15534</accession>
      <name>Nitrazepam</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba-a receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>postsynaptic membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:4</chromosome_location>
    <locus>4p12</locus>
    <gene_sequence>&gt;1425 bp
ATGTGGACAGTACAAAATCGAGAGAGTCTGGGGCTTCTCTCTTTCCCTGTGATGATTACC
ATGGTCTGTTGTGCACACAGCACCAATGAACCCAGCAACATGCCATACGTGAAAGAGACA
GTGGACAGATTGCTCAAAGGATATGACATTCGCTTGCGGCCGGACTTCGGAGGGCCCCCC
GTCGACGTTGGGATGCGGATCGATGTCGCCAGCATAGACATGGTCTCCGAAGTGAATATG
GATTATACACTCACCATGTATTTCCAGCAGTCTTGGAAAGACAAAAGGCTTTCTTATTCT
GGAATCCCACTGAACCTCACCCTAGACAATAGGGTAGCTGACCAACTCTGGGTACCAGAC
ACCTACTTTCTGAATGACAAGAAATCATTTGTGCATGGGGTCACAGTGAAAAATCGAATG
ATTCGACTGCATCCTGATGGAACAGTTCTCTATGGACTCCGAATCACAACCACAGCTGCA
TGTATGATGGATCTTCGAAGATATCCACTGGATGAGCAGAACTGCACCCTGGAGATCGAA
AGTTATGGCTATACCACTGATGACATTGAATTTTACTGGAATGGAGGAGAAGGGGCAGTC
ACTGGTGTTAATAAAATCGAACTTCCTCAATTTTCAATTGTTGACTACAAGATGGTGTCT
AAGAAGGTGGAGTTCACAACAGGAGCGTATCCACGACTGTCACTAAGTTTTCGTCTAAAG
AGAAACATTGGTTACTTCATTTTGCAAACCTACATGCCTTCTACACTGATTACAATTCTG
TCCTGGGTGTCTTTTTGGATCAACTATGATGCATCTGCAGCCAGAGTCGCACTAGGAATC
ACGACGGTGCTTACAATGACAACCATCAGCACCCACCTCAGGGAGACCCTGCCAAAGATC
CCTTATGTCAAAGCGATTGATATTTATCTGATGGGTTGCTTTGTGTTTGTGTTCCTGGCT
CTGCTGGAGTATGCCTTTGTAAATTACATCTTCTTTGGGAAAGGCCCTCAGAAAAAGGGA
GCTAGCAAACAAGACCAGAGTGCCAATGAGAAGAATAAACTGGAGATGAATAAAGTCCAG
GTCGACGCCCACGGTAACATTCTCCTCAGCACCCTGGAAATCCGGAATGAGACGAGTGGC
TCGGAAGTGCTCACGAGCGTGAGCGACCCCAAGGCCACCATGTACTCCTATGACAGCGCC
AGCATCCAGTACCGCAAGCCCCTGAGCAGCCGCGAGGCCTACGGGCGCGCCCTGGACCGG
CACGGGGTACCCAGCAAGGGGCGCATCCGCAGGCGTGCCTCCCAGCTCAAAGTCAAGATC
CCCGACTTGACTGATGTGAATTCCATAGACAAGTGGTCCCGAATGTTTTTCCCCATCACC
TTTTCTCTTTTTAATGTCGTCTATTGGCTTTACTATGTACACTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>474</residue_number>
    <molecular_weight>54234.1</molecular_weight>
    <theoretical_pi>9.01</theoretical_pi>
    <pfams>
      <pfam>
        <name>Neur_chan_LBD</name>
        <pfam_id>PF02931</pfam_id>
      </pfam>
      <pfam>
        <name>Neur_chan_memb</name>
        <pfam_id>PF02932</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>246-267</region>
      <region>271-293</region>
      <region>305-327</region>
      <region>452-473</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-25</region>
    </signal_regions>
    <protein_sequence>&gt;Gamma-aminobutyric acid receptor subunit beta-1
MWTVQNRESLGLLSFPVMITMVCCAHSTNEPSNMSYVKETVDRLLKGYDIRLRPDFGGPP
VDVGMRIDVASIDMVSEVNMDYTLTMYFQQSWKDKRLSYSGIPLNLTLDNRVADQLWVPD
TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE
SYGYTTDDIEFYWNGGEGAVTGVNKIELPQFSIVDYKMVSKKVEFTTGAYPRLSLSFRLK
RNIGYFILQTYMPSTLITILSWVSFWINYDASAARVALGITTVLTMTTISTHLRETLPKI
PYVKAIDIYLMGCFVFVFLALLEYAFVNYIFFGKGPQKKGASKQDQSANEKNKLEMNKVQ
VDAHGNILLSTLEIRNETSGSEVLTSVSDPKATMYSYDSASIQYRKPLSSREAYGRALDR
HGVPSKGRIRRRASQLKVKIPDLTDVNSIDKWSRMFFPITFSLFNVVYWLYYVH</protein_sequence>
  </protein_properties>
  <genbank_protein_id>31635</genbank_protein_id>
  <uniprot_id>P18505</uniprot_id>
  <uniprot_name>GBRB1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>X14767</genbank_gene_id>
  <genecard_id>GABRB1</genecard_id>
  <geneatlas_id>GABRB1</geneatlas_id>
  <hgnc_id>HGNC:4081</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Schofield PR, Pritchett DB, Sontheimer H, Kettenmann H, Seeburg PH: Sequence and expression of human GABAA receptor alpha 1 and beta 1 subunits. FEBS Lett. 1989 Feb 27;244(2):361-4.</reference_text>
      <pubmed_id>2465923</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kirkness EF, Kusiak JW, Fleming JT, Menninger J, Gocayne JD, Ward DC, Venter JC: Isolation, characterization, and localization of human genomic DNA encoding the beta 1 subunit of the GABAA receptor (GABRB1). Genomics. 1991 Aug;10(4):985-95.</reference_text>
      <pubmed_id>1655634</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Garrett KM, Saito N, Duman RS, Abel MS, Ashton RA, Fujimori S, Beer B, Tallman JF, Vitek MP, Blume AJ: Differential expression of gamma-aminobutyric acidA receptor subunits.  Mol Pharmacol. 1990 May;37(5):652-7.</reference_text>
      <pubmed_id>2160058</pubmed_id>
    </reference>
    <reference>
      <reference_text>Coon H, Sobell J, Heston L, Sommer S, Hoff M, Holik J, Umar F, Robertson M, Reimherr F, Wender P, et al.: Search for mutations in the beta 1 GABAA receptor subunit gene in patients with schizophrenia. Am J Med Genet. 1994 Mar 15;54(1):12-20.</reference_text>
      <pubmed_id>8178835</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yu LR, Zhu Z, Chan KC, Issaq HJ, Dimitrov DS, Veenstra TD: Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res. 2007 Nov;6(11):4150-62. Epub 2007 Oct 9.</reference_text>
      <pubmed_id>17924679</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Cole LM, Roush RT, Casida JE: Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala--&gt;Ser or Gly mutants of Rdl subunit. Life Sci. 1995;56(10):757-65.</reference_text>
        <pubmed_id>7885191</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Sauviat MP, Pages N: [Cardiotoxicity of lindane, a gamma isomer of hexachlorocyclohexane]  J Soc Biol. 2002;196(4):339-48.</reference_text>
        <pubmed_id>12645305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Anand M, Agrawal AK, Rehmani BN, Gupta GS, Rana MD, Seth PK: Role of GABA receptor complex in low dose lindane (HCH) induced neurotoxicity: neurobehavioural, neurochemical and electrophysiological studies. Drug Chem Toxicol. 1998 Feb;21(1):35-46.</reference_text>
        <pubmed_id>9530529</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Joy RM, Walby WF, Stark LG, Albertson TE: Lindane blocks GABAA-mediated inhibition and modulates pyramidal cell excitability in the rat hippocampal slice. Neurotoxicology. 1995 Summer;16(2):217-28.</reference_text>
        <pubmed_id>7566682</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Bloomquist JR: Chloride channels as tools for developing selective insecticides.  Arch Insect Biochem Physiol. 2003 Dec;54(4):145-56.</reference_text>
        <pubmed_id>14635176</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Narahashi T: Neuronal ion channels as the target sites of insecticides.  Pharmacol Toxicol. 1996 Jul;79(1):1-14.</reference_text>
        <pubmed_id>8841090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Vale C, Fonfria E, Bujons J, Messeguer A, Rodriguez-Farre E, Sunol C: The organochlorine pesticides gamma-hexachlorocyclohexane (lindane), alpha-endosulfan and dieldrin differentially interact with GABA(A) and glycine-gated chloride channels in primary cultures of cerebellar granule cells. Neuroscience. 2003;117(2):397-403.</reference_text>
        <pubmed_id>12614680</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lindane</name>
        <accession>HMDB14575</accession>
      </metabolite>
      <reference>
        <reference_text>Heusinkveld HJ, Thomas GO, Lamot I, van den Berg M, Kroese AB, Westerink RH: Dual actions of lindane (gamma-hexachlorocyclohexane) on calcium homeostasis and exocytosis in rat PC12 cells. Toxicol Appl Pharmacol. 2010 Oct 1;248(1):12-9. Epub 2010 Jun 21.</reference_text>
        <pubmed_id>20600211</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Lahti RA, Sethy VH, Barsuhn C, Hester JB: Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology. 1983 Nov;22(11):1277-82.</reference_text>
        <pubmed_id>6320036</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Sethy VH, Collins RJ, Daniels EG: Determination of biological activity of adinazolam and its metabolites.  J Pharm Pharmacol. 1984 Aug;36(8):546-8.</reference_text>
        <pubmed_id>6148400</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Halazepam</name>
        <accession>HMDB14939</accession>
      </metabolite>
      <reference>
        <reference_text>Iorio LC, Barnett A, Billard W: Selective affinity of 1-N-trifluoroethyl benzodiazepines for cerebellar type 1 receptor sites. Life Sci. 1984 Jul 2;35(1):105-13.</reference_text>
        <pubmed_id>6738302</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Halazepam</name>
        <accession>HMDB14939</accession>
      </metabolite>
      <reference>
        <reference_text>Wamsley JK, Golden JS, Yamamura HI, Barnett A: Autoradiographic demonstration of the selectivity of two 1-N-trifluoroethyl benzodiazepines for the BZD-1 receptors in the rat brain. Pharmacol Biochem Behav. 1985 Dec;23(6):973-8.</reference_text>
        <pubmed_id>2867566</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estazolam</name>
        <accession>HMDB15346</accession>
      </metabolite>
      <reference>
        <reference_text>Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain.  Eur J Pharmacol. 1978 Apr 1;48(3):263-70.</reference_text>
        <pubmed_id>639854</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estazolam</name>
        <accession>HMDB15346</accession>
      </metabolite>
      <reference>
        <reference_text>Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601.</reference_text>
        <pubmed_id>2889803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gamma Hydroxybutyric Acid</name>
        <accession>HMDB15507</accession>
      </metabolite>
      <reference>
        <reference_text>Maitre M, Humbert JP, Kemmel V, Aunis D, Andriamampandry C: [A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse].  Med Sci (Paris). 2005 Mar;21(3):284-9.</reference_text>
        <pubmed_id>15745703</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromazepam</name>
        <accession>HMDB15511</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clotiazepam</name>
        <accession>HMDB15512</accession>
      </metabolite>
      <reference>
        <reference_text>Mandrioli R, Mercolini L, Raggi MA: Benzodiazepine metabolism: an analytical perspective.  Curr Drug Metab. 2008 Oct;9(8):827-44.</reference_text>
        <pubmed_id>18855614</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fludiazepam</name>
        <accession>HMDB15513</accession>
      </metabolite>
      <reference>
        <reference_text>Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9.</reference_text>
        <pubmed_id>2857046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8.</reference_text>
        <pubmed_id>15009644</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Blaschke G, Kley H, Muller WE: [Racemation of the benzodiazepines camazepam and ketazolam and receptor binding of enantiomers]. Arzneimittelforschung. 1986 Jun;36(6):893-4.</reference_text>
        <pubmed_id>2874815</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazepam</name>
        <accession>HMDB15527</accession>
      </metabolite>
      <reference>
        <reference_text>Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49.</reference_text>
        <pubmed_id>7773620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy.  Epilepsia. 1986;27 Suppl 1:S3-13.</reference_text>
        <pubmed_id>3017690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87.</reference_text>
        <pubmed_id>2892106</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinolazepam</name>
        <accession>HMDB15533</accession>
      </metabolite>
      <reference>
        <reference_text>Walash MI, Belal F, Metwally ME, Hefnawy MM: A selective fluorimetric method for the determination of some 1,4-benzodiazepine drugs containing a hydroxyl group at C-3. J Pharm Biomed Anal. 1994 Nov;12(11):1417-23.</reference_text>
        <pubmed_id>7849137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
